KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Common Equity (2016 - 2025)

Pfizer (PFE) has disclosed Common Equity for 17 consecutive years, with $86.8 billion as the latest value for Q4 2025.

  • Quarterly Common Equity fell 1.95% to $86.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.8 billion through Dec 2025, down 1.95% year-over-year, with the annual reading at $86.8 billion for FY2025, 1.95% down from the prior year.
  • Common Equity for Q4 2025 was $86.8 billion at Pfizer, down from $93.1 billion in the prior quarter.
  • The five-year high for Common Equity was $101.2 billion in Q2 2023, with the low at $35.7 billion in Q4 2021.
  • Average Common Equity over 5 years is $86.0 billion, with a median of $89.2 billion recorded in 2023.
  • The sharpest move saw Common Equity skyrocketed 160.16% in 2022, then fell 11.4% in 2024.
  • Over 5 years, Common Equity stood at $77.5 billion in 2021, then increased by 23.82% to $95.9 billion in 2022, then decreased by 6.91% to $89.3 billion in 2023, then dropped by 0.89% to $88.5 billion in 2024, then decreased by 1.95% to $86.8 billion in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $86.8 billion, $93.1 billion, and $89.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.